Hematogenix Launches Comprehensive Molecular Profiling Test iDNAfy

iDNAfyTM brings a holistic approach to guided therapies by screening and confirming high-relevance somatic mutations. The targeted identification of these mutations in tumor suppressors and key oncogenes will provide crucial information for the oncologist to use as a guide when deciding on the appropriate therapies and personalized cancer treatments for their patients.

Tinley Park, IL /PRNewswire-iReach/ - Hematogenix Laboratory Services (Hematogenix), a leader in integrated pathology services for drug development and personalized diagnostics, today announced the launch of its comprehensive molecular profiling service, iDNAfyTM. Available through the company's Pharma and Diagnostic Service arms, the service provides Oncology clients with actionable information to optimize targeted cancer therapy for their patients.

iDNAfyTM brings a holistic approach to guided therapies by screening and confirming high-relevance somatic mutations. The targeted identification of these mutations in tumor suppressors and key oncogenes will provide crucial information for the oncologist to use as a guide when deciding on the appropriate therapies and personalized cancer treatments for their patients.

"Physicians are able to personalize treatments for their patients like never before using the molecular profiles of cancer tissue samples, and we are delighted to introduce a service that adds such value to the process," said Dr. Hytham Al‐Masri, CEO and President of Hematogenix. "IDNAfyTM will provide an efficient and cost effective approach to identifying genetic mutations that help connect patients' tumors with the appropriate drug of choice by their physician, and our report will assist in matching them with innovative clinical trials."

Hematogenix has incorporated Agena Bioscience's MassARRAY® system into its existing technologies to support the launch of its Tumor Profiling Services, which complements existing platforms with a more comprehensive testing menu.

"Physicians have the benefit of working with our Pathologists to choose from existing technologies such as IHC, FISH/ISH, and PCR to personalize testing in our full service oncology laboratory," said Dr. Al-Masri. "Today, results of molecular profiling can contraindicate chemotherapy altogether in favor of other therapies, and iDNAfyTM is a critical aid to this process."

About Hematogenix
Hematogenix is a CAP, CLIA (Clinical Laboratory Improvement Amendments) certified laboratory with a full complement of board certified clinical, anatomic and research pathologists to provide consultation and guidance for all aspects of their pharma and diagnostic services. The company offers a comprehensive array of biomarker development and testing services designed to navigate the complexities of human subject clinical trials. Hematogenix provides logistic management of tissue and sample procurement, distributes collection kits and contributes to standards and procedures required for initiating a clinical trial. Powered by a state‐of‐the‐art laboratory information system, Hematogenix facilities and practices comply with rigorous chain of custody and specimen management practices. Learn more about Hematogenix biomarker and diagnostic services at www.hematogenix.com.

News distributed by PR Newswire iReach: https://ireach.prnewswire.com